阿伐可泮治疗抗中性粒细胞胞质抗体相关性血管炎:一项多中心真实世界研究
这项多中心回顾性研究纳入31例对高剂量糖皮质激素有禁忌的AAV患者,在法国早期准入计划下接受阿伐可泮30 mg每日两次联合标准治疗。25例(81%)结局良好且无严重不良事件,估算肾小球滤过率从19升至35 mL/min/1.73 m2(P < 0.05),但作者认为需进一步研究确定阿伐可泮使用时的最佳糖皮质激素剂量。
要点
- 31例AAV患者中30例有肾脏血管炎,25例(81%)结局良好且无严重不良事件。
- 估算肾小球滤过率从19升至35 mL/min/1.73 m2(P < 0.05),与肾活检结果无关。
- 1例发生难治性AAV、2例复发,2例因严重不良事件停用阿伐可泮。
核心结论
- 阿伐可泮的糖皮质激素节约效应得到证实,即使在严重肾脏血管炎患者中亦然,但需进一步研究以确定使用阿伐可泮时糖皮质激素的最佳剂量。
研究设计与样本
- 多中心回顾性研究,回顾2020年至2023年法国早期准入计划下接受阿伐可泮30 mg每日两次联合标准治疗的AAV且对高剂量糖皮质激素有禁忌患者的临床病历,共31例,使用标准化病例报告表记录疗效与安全性数据。
主要发现
- 31例患者中位年龄72岁,10例为复发性AAV,20例抗髓过氧化物酶抗体阳性,30例有肾脏血管炎。
- 诱导方案包括利妥昔单抗(n = 27)、环磷酰胺(n = 2)或两者联用(n = 2);5例未接受糖皮质激素。
- 尽管快速减撤糖皮质激素(23例在第3个月前停用),25例(81%)结局良好且无严重不良事件。
- 估算肾小球滤过率从19 [15; 34]升至35 mL/min/1.73 m2 [23; 45](第12个月,P < 0.05),与肾活检结果无关。
- 1例发生难治性AAV,2例在接受阿伐可泮期间复发;第12个月时18例中10例(55.5%)ANCA仍阳性;2例发生导致停用阿伐可泮的严重不良事件(肝炎和年龄相关性黄斑变性)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 进一步研究是必要的,以确定使用阿伐可泮时糖皮质激素的最佳剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Avacopan, a selective C5aR1 inhibitor, recently emerged as a glucocorticoid (GCs) sparing agent in anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitis (AAV). We aim to evaluate the tolerance and efficacy of avacopan given outside randomized clinical trials or with severe kidney involvement. METHODS: In this multicentre retrospective study, we reviewed the clinical charts of patients with AAV and contraindication to high dose of GCs who received avacopan 30 mg b.i.d plus standard-of-care regimen owing to the French early access program between 2020 and 2023. Efficacy and safety data were recorded using a standardized case report form. RESULTS: Among the 31 patients (median age 72 years), 10 had a relapsing AAV, 20 had anti-myeloperoxidase antibodies and 30 had kidney vasculitis. Induction regimen included rituximab (n = 27), cyclophosphamide (n = 2) or both (n = 2). Five patients did not receive GCs. Despite rapid GCs tapering (which were withdrawn in 23 patients before month 3), 25 patients (81%) had a favourable outcome and no severe adverse event. The estimated glomerular filtration rate increased from 19 [15; 34] to 35 mL/min/1.73 m2 [23; 45] at month 12 (P < 0.05), independently of kidney biopsies findings. One patient developed refractory AAV and two had a relapse while receiving avacopan. At month 12, ANCA remained positive in 10/18 patients (55.5%). Two patients developed severe adverse events leading to a withdrawal of avacopan (hepatitis and age-related macular degeneration). CONCLUSIONS: The GCs' sparing effect of avacopan was confirmed, even in patients with severe kidney vasculitis, but further studies are required to identify the optimal dosing of GCs when avacopan is used.
引用
- Gabilan C, Belliere J, Moranne O, et al. Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study. Rheumatology (Oxford). 2025. PMID: 39001799. doi:10.1093/rheumatology/keae359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。